Press release

Moderna Finalizes Agreement with the Government of the Republic of Kenya to Establish an mRNA Manufacturing Facility

Facility to enable access to manufactured mRNA vaccines for Kenya and the African continent, providing health security and building upon Moderna's global

articleModerna, Inc.March 30, 20234/company/moderna-inc/news/moderna-finalizes-agreement-with-the-government-of-the-republic-of-kenya-to-establish
Moderna Finalizes Agreement with the Government of the Republic of Kenya to Establish an mRNA Manufacturing Facility

About this update from Moderna, Inc.

[{"type":"text","content":"Facility to enable access to manufactured mRNA vaccines for Kenya and the African continent, providing health security and building upon Moderna's global public health commitmentsThe facility will be capable of producing up to 500 million doses each yearCAMBRIDGE, MA & NAIROBI, KENYA / ACCESSWIRE / March 30, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and the Government of the Republic of Kenya have finalized an agreement to establish an mRNA manufacturing facility in the Republic of Kenya. This will be the Company's first mRNA manufacturing facility in Africa.In partnership with the Government of the Republic of Kenya, Moderna will build a state-of-the-art mRNA facility in Kenya to produce up to 500 million doses of vaccines each year. The Company expects the new facility to enable drug substance and drug product manufacturing for Kenya and the African continent. In addition, this facility will have surge capacity to rapidly scale and respond to public health emergencies on the continent and around the world.\"The finalization of our agreement with the Government of the Republic of Kenya is a key pillar of our global public health strategy, where we hope to bring mRNA innovation to the people of Africa in areas of high unmet need, such as acute respiratory infections, as well as persistent infectious diseases like HIV and outbreak threats such as Zika and Ebola,\" said Stéphane Bancel, Chief Executive Officer of Moderna. \"This also demonstrates our confidence in the investment climate in Kenya and the importance of utilizing mRNA technology to build resilience in healthcare security in Africa. We are also grateful for the leadership of the U.S. Ambassador to Kenya, Meg Whitman, and Samantha Power, in her role as Administrator of the United States Agency for International Development for their instrumental support of this project.\"\"We are excited about this milestone that brings to bear our efforts as Government to sustain our economic model of facilitating investments that serve not only Kenya but the African continent. My Government commits to supporting this investment as a critical signal to the investment community that Kenya is open for business,\" said President William Ruto.\"This investment creates the momentum to meet the $10 billion annual t...

More updates from Moderna, Inc.